Literature DB >> 15297486

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Frank C Odds1, Mary Motyl, Roberto Andrade, Jacques Bille, Emilia Cantón, Manuel Cuenca-Estrella, Amanda Davidson, Christian Durussel, David Ellis, Elyse Foraker, Annette W Fothergill, Mahmoud A Ghannoum, Robert A Giacobbe, Miguel Gobernado, Rosemary Handke, Michel Laverdière, Wendy Lee-Yang, William G Merz, Luis Ostrosky-Zeichner, Javier Pemán, Sophia Perea, John R Perfect, Michael A Pfaller, Laurie Proia, John H Rex, Michael G Rinaldi, Juan-Luis Rodriguez-Tudela, Wiley A Schell, Christine Shields, Deanna A Sutton, Paul E Verweij, David W Warnock.   

Abstract

Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC(2)) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode +/- one dilution range across all 17 laboratories. MIC(2) at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297486      PMCID: PMC497639          DOI: 10.1128/JCM.42.8.3475-3482.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors:  Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species.

Authors:  Rama Ramani; Vishnu Chaturvedi
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

6.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

7.  Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables.

Authors:  B Rambali; J A Fernandez; L Van Nuffel; F Woestenborghs; L Baert; D L Massart; F C Odds
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

8.  Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods.

Authors:  M Laverdiere; C Restieri; F Habel
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

9.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

Authors:  Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  80 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 2.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Authors:  Jason Cota; Michael Carden; John R Graybill; Laura K Najvar; David S Burgess; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Flow cytometry susceptibility testing for the antifungal caspofungin.

Authors:  M Mitchell; M Hudspeth; A Wright
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.

Authors:  A Espinel-Ingroff; A Fothergill; M Ghannoum; E Manavathu; L Ostrosky-Zeichner; M A Pfaller; M G Rinaldi; W Schell; T J Walsh
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

8.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

Authors:  Guy St-Germain; Michel Laverdière; René Pelletier; Pierre René; Anne-Marie Bourgault; Claude Lemieux; Michael Libman
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

9.  Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

Review 10.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.